Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

2 treatments under study, led by Emapalumab

Research Leaders

6 sponsors active, led by Ministry of Health, Russian Federation

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

100%

2 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Phase 3 (2)

Trial Status

Completed1
Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT05001737Phase 3Completed

Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

NCT05432960Phase 3Withdrawn

Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)

Showing all 2 trials

Research Network

Common Treatments

  • Emapalumab1
  • Goflikicept1

Active Sponsors

  • Ministry of Health, Russian Federation1
  • R-Pharm International, LLC1
  • Exacte Labs LLC1
  • Scientific Center EFiS LLC1
  • Swedish Orphan Biovitrum1

Top Investigators

Related Conditions

  • Mas1
  • Adultonset Stills Disease1
  • Sjia1
  • Systemic Lupus Erythematosus1
  • Macrophage Activation Syndrome1

Activity Timeline